Drug Trial Radar · NCT02278315
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Feb 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Feb 2015
Primary completion
Dec 9, 2020
Study completion Aug 10, 2022
Sponsor
- Lead sponsor
- Cellectar Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
Conditions
- Multiple Myeloma
Interventions
I-131-CLR1404Drug
Single IV dose of I-131-CLR1404, increased/decreased by cohort
dexamethasoneDrug
40 mg dexamethasone orally once weekly for up to 12 weeks
I-131-CLR1404Drug
Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLT)Time frame: up to 85 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Jacksonville, Florida
Loyola University Medical Center
Maywood, Illinois
Karmanos Cancer Institute
Detroit, Michigan
University of Wisconsin Hospital and Clinics
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.